BTL Initiates Patent Infringement Lawsuit Against WonderFace Device
On October 8, 2025, BTL Group, a leading global provider of medical solutions, confirmed that it has initiated an international patent infringement lawsuit against Lexter Microelectronic Engineering Systems S.L. This legal action was filed with the Unified Patent Court and pertains specifically to Lexter's WonderFace device.
The lawsuit is centered on BTL's patents related to EMFACE®, a pioneering technology that has transformed the facial lifting industry. This innovative system combines selective muscle stimulation with radiofrequency heating through distinctive hands-free applicators, thereby creating a completely new category of facial procedures. EMFACE® is recognized for its efficacy and safety, greatly enhancing the non-invasive treatment options available in aesthetic medicine.
Tomas Schwarz, the Chief Executive Officer of BTL Enterprise Group, stated, "We will vigorously defend our intellectual property to safeguard our clients' investments. This lawsuit marks the beginning of a broader initiative to legally challenge any parties we believe infringe our innovations." He emphasized the importance of protecting their patents to ensure the integrity of their products and the competitive edge in the market.
The outcome of this legal proceeding has significant implications, as it aims to prevent the distribution of WonderFace systems in various countries. The judgment is expected to affect 18 jurisdictions, showcasing the extensive reach and impact of this enforcement initiative. This underscores BTL's commitment to upholding its intellectual property rights and maintaining the integrity of its product offerings.
For those interested in learning more about EMFACE and its revolutionary approach, additional information is available at www.emface.com.
Founded in 1993, BTL is at the forefront of medical device innovation, providing solutions in a wide range of fields, including dermatology, plastic surgery, medical spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary healthcare, obstetrics, and gynecology, among others. With over 200 patents and more than 600 in-house engineers, BTL harnesses technology and science to advance medical treatments. Their product portfolio includes EMFACE®, EXION®, EMSCULPT NEO®, EXOMIND®, EMSELLA®, and more.
In a rapidly evolving medical landscape, the need for strong intellectual property protection has never been more critical. As BTL pursues this legal action, the industry will undoubtedly be watching closely to see how the court’s ruling shapes the future of aesthetic treatments and medical innovations.
For press inquiries, please contact Daniela Rickova at [email protected].
The lawsuit is centered on BTL's patents related to EMFACE®, a pioneering technology that has transformed the facial lifting industry. This innovative system combines selective muscle stimulation with radiofrequency heating through distinctive hands-free applicators, thereby creating a completely new category of facial procedures. EMFACE® is recognized for its efficacy and safety, greatly enhancing the non-invasive treatment options available in aesthetic medicine.
Tomas Schwarz, the Chief Executive Officer of BTL Enterprise Group, stated, "We will vigorously defend our intellectual property to safeguard our clients' investments. This lawsuit marks the beginning of a broader initiative to legally challenge any parties we believe infringe our innovations." He emphasized the importance of protecting their patents to ensure the integrity of their products and the competitive edge in the market.
The outcome of this legal proceeding has significant implications, as it aims to prevent the distribution of WonderFace systems in various countries. The judgment is expected to affect 18 jurisdictions, showcasing the extensive reach and impact of this enforcement initiative. This underscores BTL's commitment to upholding its intellectual property rights and maintaining the integrity of its product offerings.
For those interested in learning more about EMFACE and its revolutionary approach, additional information is available at www.emface.com.
Founded in 1993, BTL is at the forefront of medical device innovation, providing solutions in a wide range of fields, including dermatology, plastic surgery, medical spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary healthcare, obstetrics, and gynecology, among others. With over 200 patents and more than 600 in-house engineers, BTL harnesses technology and science to advance medical treatments. Their product portfolio includes EMFACE®, EXION®, EMSCULPT NEO®, EXOMIND®, EMSELLA®, and more.
In a rapidly evolving medical landscape, the need for strong intellectual property protection has never been more critical. As BTL pursues this legal action, the industry will undoubtedly be watching closely to see how the court’s ruling shapes the future of aesthetic treatments and medical innovations.
For press inquiries, please contact Daniela Rickova at [email protected].
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.